Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Safety and efficacy of IL-12 plasmid DNA transfection into pig skin : supportive data for human clinical trials on gene therapy and vaccination
Authors:ID Lampreht Tratar, Urša (Author)
ID Jesenko, Tanja (Author)
ID Omerzel, Maša (Author)
ID Seliškar, Alenka (Author)
ID Stupan, Urban (Author)
ID Djokić, Mihajlo (Author)
ID Sredenšek, Jerneja (Author)
ID Trotovšek, Blaž (Author)
ID Serša, Gregor (Author)
ID Čemažar, Maja (Author)
Files:URL URL - Source URL, visit https://www.mdpi.com/1422-0067/25/6/3151
 
.pdf PDF - Presentation file, download (16,83 MB)
MD5: F61407EF65A3DEE02520CB25A3B9E701
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Gene electrotransfer (GET) of plasmids encoding interleukin 12 (IL-12) has already been used for the treatment of various types of tumors in human oncology and as an adjuvant in DNA vaccines. In recent years, we have developed a plasmid encoding human IL-12 (phIL12) that is currently in a phase I clinical study. The aim was to confirm the results of a non-clinical study in mice on pharmacokinetic characteristics and safety in a porcine model that better resembled human skin. The GET of phIL12 in the skin was performed on nine pigs using different concentrations of plasmid phIL12 and invasive (needle) or noninvasive (plate) types of electrodes. The results of our study demonstrate that the GET of phIL-12 with needle electrodes induced the highest expression of IL-12 at the protein level on day 7 after the procedure. The plasmid was distributed to all tested organs; however, its amount decreased over time and was at a minimum 28 days after GET. Based on plasmid copy number and expression results, together with blood analysis, we showed that IL-12 GET is safe in a porcine animal model. Furthermore, we demonstrated that pigs are a valuable model for human gene therapy safety studies.
Keywords:interleukin 12, gene electrotransfer, immunotherapy
Publication status:Published
Publication version:Version of Record
Submitted for review:27.11.2023
Article acceptance date:06.03.2024
Publication date:09.03.2024
Publisher:MDPI
Year of publishing:2024
Number of pages:str. 3151-1-3151-12
Numbering:Vol. 25, no. 6
Source:Basel, Switzerland
PID:20.500.12556/DiRROS-18738 New window
UDC:602
ISSN on article:1422-0067
DOI:10.3390/ijms25063151 New window
COBISS.SI-ID:191795459 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 9. 4. 2024;
Publication date in DiRROS:18.04.2024
Views:543
Downloads:242
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:International journal of molecular sciences
Shortened title:Int. j. mol. sci.
Publisher:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P4-0053
Name:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:09.03.2024

Secondary language

Language:Slovenian
Keywords:interlevkin 12, elektroprenos genov, imunoterapija


Back